Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for Prevention of Niraparib-Induced Thrombocytopenia in Ovarian Cancer
NCT06036966Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in Thrombocytopenia, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Rate of thrombocytopenia according to CTCAE 5.0 at 12 weeks. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06036966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036966.